7/30/02

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 19	Jun 03	New e-mail delivery for search results now available
NEWS 20	Jun 10	MEDLINE Reload
NEWS 21	Jun 10	PCTFULL has been reloaded
NEWS 22	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 23	Jul 19	NTIS to be reloaded July 28, 2002
NEWS 24	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 25	Jul 29	Enhanced polymer searching in REGISTRY

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:14:07 ON 30 JUL 2002

=> File health medicine meetings pharmacology research toxicology
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISALERTS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISINSIGHT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'AQUASCI' ENTERED AT 12:14:14 ON 30 JUL 2002
(c) 2002 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHNO' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'CAPLUS' ENTERED AT 12:14:14 ON 30 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CHEMLIST' ENTERED AT 12:14:14 ON 30 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:14:14 ON 30 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CSNB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'EMBAL' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'ENERGY' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (c) 2002 USDOE for the IEA-Energy Technology Data Exchange (ETDE)

FILE 'ESBIOBASE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'FOMAD' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'HEALSAFE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'HSDB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 NATIONAL LIBRARY OF MEDICINE

FILE 'IFIPAT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'JICST-EPLUS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (c) 2002 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'MSDS-CCOHS' ENTERED AT 12:14:14 ON 30 JUL 2002
Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 12:14:14 ON 30 JUL 2002

COPYRIGHT (C) 2002 MDL INFORMATION SYSTEMS (MDL)

FILE 'NAPRALERT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NIOSHTIC' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NLDB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'NTIS' ENTERED AT 12:14:14 ON 30 JUL 2002
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2002)

FILE 'PASCAL' ENTERED AT 12:14:14 ON 30 JUL 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'POLLUAB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PROMT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'RTECS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government (DOC)

FILE 'SCISEARCH' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'TOXCENTER' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 ACS

FILE 'USPATFULL' ENTERED AT 12:14:14 ON 30 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:14:14 ON 30 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DDFU' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DGENE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGLAUNCH' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'PHIC' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE '1MOBILITY' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Society of Automotive Engineers, Inc.

FILE 'AGRICOLA' ENTERED AT 12:14:14 ON 30 JUL 2002

FILE 'COMPENDEX' ENTERED AT 12:14:14 ON 30 JUL 2002
Compendex Compilation and Indexing (C) 2002
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'COMPUAB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CONF' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'ELCOM' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'EVENTLINE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 ELSEVIER Publishing Group, Amsterdam

FILE 'IMSDRUGCONF' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd.

FILE 'ISMEC' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'OCEAN' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PAPERCHEM2' ENTERED AT 12:14:14 ON 30 JUL 2002
Paperchem2 compilation and indexing (C) 2002
Elsevier Engineering Information Inc. All rights reserved.

FILE 'SOLIDSTATE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'BABS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'DIOGENES' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 FOI Services, Inc. (FOI)

FILE 'DRUGUPDATES' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

```
FILE 'INVESTEXT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'PHAR' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'SYNTHLINE' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Prous Science

FILE 'USAN' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'DKF' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Dokumentation Kraftfahrwesen e.V., Germany

FILE 'FORIS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'FORKAT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Bundesministerium fuer Bildung,
Wissenschaft, Forschung und Technologie (bmb+f)

FILE 'RUSSCI' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'CABA' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'FSTA' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 International Food Information Service

FILE 'ULIDAT' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'VETB' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:14:14 ON 30 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

=> s zinc (4A) metalloprotease
  33 FILES SEARCHED...
  76 FILES SEARCHED...
L1         3253 ZINC (4A) METALLOPROTEASE

=> human (4A) metalloprotease
HUMAN IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s human (4a) metalloprotease
  11 FILES SEARCHED...
  30 FILES SEARCHED...
  45 FILES SEARCHED...
  57 FILES SEARCHED...
```

```
L2        1745 HUMAN (4A) METALLOPROTEASE

=> s matrix (4a) metalloprotease
  37 FILES SEARCHED...
  79 FILES SEARCHED...
L3        5475 MATRIX (4A) METALLOPROTEASE

=> s l1 and l2 and l3
  55 FILES SEARCHED...
L4          29 L1 AND L2 AND L3

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l4
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, CHEMLIST,
FEDRIP, FOREGE, HSDB, KOSMET, MEDICONF, MSDS-CCOHS, MSDS-OHS, RTECS, DGENE,
DRUGLAUNCH, DRUGMONOG2, CONF, EVENTLINE, IMSDRUGCONF, DIOGENES, DRUGUPDATES,
INVESTEXT, PHAR, SYNTHLINE, USAN, FORIS, FORKAT, UFORDAT'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'USPATFULL, DGENE'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L4
L5          29 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

=> d l5 1-29 bib ab

L5   ANSWER 1 OF 29  USPATFULL
AN     2002:186083  USPATFULL
TI     Inhibition of invasive remodelling
IN     Lund, Leif Roge, Copenhagen, DENMARK
       Dano, Keld, Charlottenlund, DENMARK
       Stephens, Ross, Charlottenlund, DENMARK
       Brunner, Nils, Hellerup, DENMARK
       Solberg, Helene, Hillerod, DENMARK
       Holst-Hansen, Claus, Frederiksberg C, DENMARK
       Nielsen, John Romer, Copenhagen O, DENMARK
PI     US 2002099004      A1   20020725
AI     US 2001-995636     A1   20011129 (9)
RLI    Continuation of Ser. No. US 1999-319464, filed on 27 Aug 1999, ABANDONED
       A 371 of International Ser. No. WO 1997-DK555, filed on 8 Dec 1997,
       UNKNOWN
PRAI   DK 1996-1402        19961206
DT     Utility
FS     APPLICATION
LREP   BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC,
       20001
CLMN   Number of Claims: 39
ECL    Exemplary Claim: 1
DRWN   16 Drawing Page(s)
LN.CNT 2781
AB     Invasive remodelling in a mammal may be inhibited by (1) inhibiting or
       abolishing the protein cleaving action of plasmin and (2) inhibiting or
       abolishing the protein cleaving action of at least one additional
       proteolytic enzyme active in invasive remodelling, such as a
       metalloprotease.

L5   ANSWER 2 OF 29  USPATFULL
AN     2002:141530  USPATFULL
TI     Substituted cyclic amine metalloprotease inhibitors
IN     Natchus, Michael George, Glendale, OH, UNITED STATES
       De, Biswanath, Cincinnati, OH, UNITED STATES
       Pikul, Stanislaw, Mason, OH, UNITED STATES
```

Almstead, Neil Gregory, Loveland, OH, UNITED STATES
Bookland, Roger Gunnard, Cincinnati, OH, UNITED STATES
Taiwo, Yetunde Olabisi, West Chester, OH, UNITED STATES
Cheng, Menyan, West Chester, OH, UNITED STATES
PA The Procter & Gamble Company (U.S. corporation)
PI US 2002072517 A1 20020613
AI US 2001-888759 A1 20010625 (9)
RLI Division of Ser. No. US 1997-918317, filed on 26 Aug 1997, PENDING
PRAI US 1996-24842P 19960828 (60)
DT Utility
FS APPLICATION
LREP Tanaga A. Boozer, The Procter & Gamble Company, Health Care Research Center (Box 1050), P.O. Box 8006, Mason, OH, 45040-8006
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). ##STR1##

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 3 OF 29 USPATFULL
AN 2002:141093 USPATFULL
TI Methods for identifying a protease inhibitor
IN Chadwick, Mark P., Cambridge, UNITED KINGDOM
Russell, Stephen J., Rochester, MN, UNITED STATES
PI US 2002072075 A1 20020613
AI US 2001-791426 A1 20010223 (9)
PRAI US 2000-185203P 20000225 (60)
DT Utility
FS APPLICATION
LREP Kathleen M. Williams, Ph.D., Palmer & Dodge, LLP, 111 Huntington Avenue At The Prudential Center, Boston, MA, 02199-7613
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are disclosed whereby inhibition of proteolytic activity causes an increase in delivery of a transferable label from a viral display package to a target cell. Assaying for the transferable label in the target cell in the presence of a test substance can identify the test substance as a protease inhibitor. Protease inhibitors so identified are used therapeutically, to treat conditions such as cancer, inflammation, rheumatoid arthritis and other autoimmune diseases, and infections, including AIDS, herpes, and hepatitis.

L5 ANSWER 4 OF 29 USPATFULL
AN 2002:119889 USPATFULL
TI Substituted cyclic amine metalloprotease inhibitors
IN Natchus, Michael George, Glendale, OH, UNITED STATES
De, Biswanath, Cincinnati, OH, UNITED STATES
Pikul, Stanislaw, Mason, OH, UNITED STATES
Almstead, Neil Gregory, Loveland, OH, UNITED STATES
Bookland, Roger Gunnard, Cincinnati, OH, UNITED STATES

Taiwo, Yetunde Olabisi, West Chester, OH, UNITED STATES
Cheng, Menyan, West Chester, OH, UNITED STATES
PA The Procter & Gamble Company (U.S. corporation)
PI US 2002061877 A1 20020523
AI US 2001-888675 A1 20010625 (9)
RLI Division of Ser. No. US 1997-918317, filed on 26 Aug 1997, PENDING
PRAI US 1996-24842P 19960828 (60)
DT Utility
FS APPLICATION
LREP Tanaga A. Boozer, The Procter & Gamble Company, Health Care Research Center (Box 1050), P.O. Box 8006, Mason, OH, 45040-8006
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). ##STR1##

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 5 OF 29 USPATFULL
AN 2002:168251 USPATFULL
TI Hetero-substituted cyclic amine metalloprotease inhibitors
IN Natchus, Michael George, Glendale, OH, United States
De, Biswanath, Cincinnati, OH, United States
Pikul, Stanislaw, Mason, OH, United States
Almstead, Neil Gregory, Loveland, OH, United States
Bookland, Roger Gunnard, Cincinnati, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
Cheng, Menyan, West Chester, OH, United States
PA The Proctor & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6417219 B1 20020709
AI US 1997-918317 19970826 (8)
PRAI US 1996-24842P 19960828 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stockton, Laura L.
LREP Roof, Carl J., Boozer, Tanaga A.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I). ##STR1##

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 6 OF 29 USPATFULL
AN 2002:129957 USPATFULL

TI Diheterocyclic metalloprotease inhibitors
IN Pikul, Stanislaw, Mason, OH, United States
Almstead, Neil Gregory, Loveland, OH, United States
Bradley, Rimma Sandler, Fairfield, OH, United States
McDow-Dunham, Kelly Lynn, Loveland, OH, United States
De, Biswanath, Cincinnati, OH, United States
Natchus, Michael George, Glendale, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
Cupps, Thomas Lee, Oxford, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6399598 B1 20020604
AI US 2000-516726 20000301 (9)
RLI Division of Ser. No. US 1997-918957, filed on 26 Aug 1997, now patented, Pat. No. US 6121258
PRAI US 1996-24846P 19960828 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Coleman, Brenda
LREP Roof, Carl J., Boozer, Tanaga A., Clark, Karen F.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula ##STR1##

as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptacle salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases. Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 7 OF 29 USPATFULL
AN 2002:122764 USPATFULL
TI Nucleic acid molecules encoding human protease homologs
IN Robison, Keith E., Wilmington, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6395889 B1 20020528
AI US 1999-392184 19990909 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Moore, William W.
LREP Alston & Bird LLP
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to polynucleotides encoding newly identified protease homologs. The invention also relates to the proteases. The invention further relates to methods using the protease polypeptides and polynucleotides as a target for diagnosis and treatment in protease-mediated disorders. The invention further relates to drug-screening methods using the protease polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the protease polypeptides and polynucleotides. The invention

further relates to procedures for producing the protease polypeptides and polynucleotides.

L5 ANSWER 8 OF 29 USPATFULL
AN 2002:24192 USPATFULL
TI Isolated **human metalloprotease** proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
IN Merkulov, Gennady V., Baltimore, MD, United States
Ye, Jane, Boyds, MD, United States
Di Francesco, Valentina, Rockville, MD, United States
Beasley, Ellen M., Darnestown, MD, United States
PA PE Corporation, Norwalk, CT, United States (U.S. corporation)
PI US 6344352 B1 20020205
AI US 2001-920048 20010802 (9)
RLI Division of Ser. No. US 2001-813819, filed on 22 Mar 2001, now patented, Pat. No. US 6294368
DT Utility
FS GRANTED
EXNAM Primary Examiner: Achutamurthy, Ponnathapu; Assistant Examiner: Fronda, Christian L
LREP Celera Genomics, Millman, Robert A., Sun-Hoffman, Lin
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 2909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.

L5 ANSWER 9 OF 29 USPATFULL
AN 2001:226672 USPATFULL
TI Substituted pyrrolidine hydroxamate metalloprotease inhibitors
IN Cheng, Menyan, West Chester, OH, United States
Natchus, Michael George, Glendale, OH, United States
De, Biswanath, Cincinnati, OH, United States
Almstead, Neil Gregory, Loveland, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
Pikul, Stanislaw, Mason, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6329418 B1 20011211
AI US 1999-274564 19990323 (9)
PRAI US 1998-81667P 19980414 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Balasubramanian, Venkataraman
LREP Roof, Carl J., Kellerman, James C., Boozer, Tanaga A.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1926
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds which are potent inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to compounds having a structure according to the following Formula (I): ##STR1##

wherein R.sub.1, R.sub.2, X, Z, m, and n are defined below.

to This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of diseases and conditions which are characterized by unwanted metalloprotease activity. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for metalloprotease-related maladies using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 10 OF 29 USPATFULL
AN 2001:185528 USPATFULL
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
IN Campbell, David A., 1492 Ascension Dr., San Mateo, CA, United States 94402
Patel, Dinesh V., 45109 Cougar Cir., Fremont, CA, United States 94086
Xiao, Xiao-Yi, 11025 N. Torrey Pines Rd., #100, La Jolla, CA, United States 92037
PI US 6307101 B1 20011023
AI US 1999-271801 19990317 (9)
RLI Continuation of Ser. No. US 1998-81466, filed on 19 May 1998, now patented, Pat. No. US 5929278 Continuation of Ser. No. US 1995-549345, filed on 27 Oct 1995, now patented, Pat. No. US 5831004 Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jones, Dwayne C.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Townsend and Townsend and Crew LLP
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel inhibitors of **metalloproteases**, in particular **matrix metalloproteases**. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 11 OF 29 USPATFULL
AN 2001:163038 USPATFULL
TI Isolated **human metalloprotease** proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
IN Merkulov, Gennady V., Baltimore, MD, United States
Ye, Jane, Boyds, MD, United States
Di Francesco, Valentina, Rockville, MD, United States
Beasley, Ellen M., Darnestown, MD, United States
PA Applera Corporation, Norwalk, CT, United States (U.S. corporation)
PI US 6294368 B1 20010925
AI US 2001-813819 20010322 (9)
DT Utility
FS GRANTED

EXNAM Primary Examiner: Nashed, Nashaat T.; Assistant Examiner: Fronda, Christian L.
LREP Genomics, Celera, Millman, Robert A., Sun-Hoffman, Lin
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 2334
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.

L5 ANSWER 12 OF 29 USPATFULL
AN 2001:102574 USPATFULL
TI Disintegrin metalloprotease and its use
IN Tindal, Michael Howard, Wyoming, OH, United States
Haqqi, Tariq Mehmood, Cleveland Heights, OH, United States
PA The Procter & Gamble Company, Mason, OH, United States (U.S. corporation)
Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 6255064 B1 20010703
AI US 1998-30335 19980225 (9)
RLI Continuation-in-part of Ser. No. WO 1997-US3217, filed on 28 Feb 1997
Continuation-in-part of Ser. No. US 1997-810153, filed on 25 Feb 1997, now abandoned
PRAI US 1996-12679P 19960301 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Slobodyansky, Elizabeth
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1176
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Proteins comprising the amino acid sequence of human disintegrin and DNA sequences encoding the human disintegrin protein are identified. Also described are methods for determining the activity of the disintegrin and for identifying compounds capable of binding to and inhibiting the disintegrin protein. Recombinant expression vectors comprising the DNA sequences encoding the disintegrin, host cells comprising the recombinant expression vector, and antibodies to the disintegrin protein and screening methods for detecting levels of disintegrin protein are exemplified.

L5 ANSWER 13 OF 29 USPATFULL
AN 2001:33267 USPATFULL
TI Alkenyl- and alkynl-containing metalloprotease inhibitors
IN Natchus, Michael George, Glendale, OH, United States
Bookland, Roger Gunnard, Cincinnati, OH, United States
Almstead, Neil Gregory, Loveland, OH, United States
Pikul, Stanislaw, Mason, OH, United States
De, Biswanath, Cincinnati, OH, United States
Cheng, Menyan, West Chester, OH, United States
PA The Procter & Gamble Co., Cincinnati, OH, United States (U.S. corporation)
PI US 6197770 B1 20010306
AI US 2000-517080 20000301 (9)
PRAI US 1999-122644P 19990303 (60)

DT Utility
FS Granted
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP Roof, Carl J., Clark, Karen F.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4321
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): ##STR1##

where X, W, Z, A, G, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.5' and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

L5 ANSWER 14 OF 29 USPATFULL
AN 2000:125049 USPATFULL
TI Bidentate metalloprotease inhibitors
IN Almstead, Neil Gregory, Loveland, OH, United States
De, Biswanath, Cincinnati, OH, United States
Bradley, Rimma Sandler, Fairfield, OH, United States
Garrett, Garry Steven, Cincinnati, OH, United States
Marlin, II, John Emory, Bridgewater, NJ, United States
McIver, John McMillan, Cincinnati, OH, United States
Wang, Zhe, Hockessin, DE, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6121272 20000919
AI US 1997-918318 19970826 (8)
PRAI US 1996-24746P 19960828 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Sripada, Pavanaram K
LREP Roof, Carl J., Suter, David L.
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds which are useful as inhibitors of metalloproteases, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I) ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, ester, acyloxyamide, or imide thereof. Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 15 OF 29 USPATFULL

AN 2000:125035 USPATFULL
TI 1,5-heterocyclic metalloprotease inhibitors
IN Pikul, Stanislaw, Mason, OH, United States
Almstead, Neil Gregory, Loveland, OH, United States
Bradley, Rimma Sandler, Fairfield, OH, United States
McDow-Dunham, Kelly Lynn, Loveland, OH, United States
De, Biswanath, Cincinnati, OH, United States
Natchus, Michael George, Glendale, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
Cupps, Thomas Lee, Norwich, NY, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6121258 20000919
AI US 1997-918957 19970826 (8)
PRAI US 1996-24846P 19960828 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Coleman, Brenda
LREP Roof, Carl J., Suter, David L.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases.

Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 16 OF 29 USPATFULL
AN 2000:7413 USPATFULL
TI Spirocyclic containing hydroxamic acids useful as metalloprotease inhibitors
IN Wang, Zhe, Wilmington, DE, United States
Almstead, Neil Gregory, Loveland, OH, United States
Bradley, Rimma Sandler, Fairfield, OH, United States
Natchus, Michael George, Glendale, OH, United States
De, Biswanath, Cincinnati, OH, United States
Pikul, Stanislaw, Mason, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 6015912 20000118
AI US 1997-918328 19970826 (8)
PRAI US 1996-24766P 19960828 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.
LREP Roof, Carl J., Suter, David L., Rasser, Jacobus C.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2616
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of formula ##STR1## as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or

imide thereof are useful as inhibitors of metalloproteases.

Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 17 OF 29 USPATFULL
AN 1999:151215 USPATFULL
TI Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
IN Campbell, David, San Mateo, CA, United States
Look, Gary C., Santa Clara, CA, United States
Szardenings, Anna Katrin, Santa Clara, CA, United States
Patel, Dinesh V., Fremont, CA, United States
PA Affymax Technologies N.V., Greenford, United Kingdom (non-U.S. corporation)
PI US 5990112 19991123
AI US 1996-670713 19960618 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Bernhardt, Emily
LREP Swiss, Gerald F., Stevens, Lauren L.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel inhibitors of metalloproteases are disclosed. Such compounds are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, such as rheumatoid arthritis.

L5 ANSWER 18 OF 29 USPATFULL
AN 1999:85629 USPATFULL
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
IN Campbell, David A., San Mateo, CA, United States
Patel, Dinesh V., Fremont, CA, United States
Xiao, Xiao-Yi, La Jolla, CA, United States
PA Affymax Technologies N.V., Greenford, United Kingdom (non-U.S. corporation)
PI US 5929278 19990727
AI US 1998-81466 19980519 (9)
RLI Continuation of Ser. No. US 1995-549345, filed on 27 Oct 1995, now patented, Pat. No. US 5831004 which is a continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Swiss, Gerald F., Stevens, Lauren L.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel inhibitors of **metalloproteases**, in particular **matrix metalloproteases**. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are

useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 19 OF 29 USPATFULL
AN 1999:43850 USPATFULL
TI Process for preparing synthetic **matrix metalloprotease** inhibitors
IN Levy, Daniel E., Alameda, CA, United States
Grobelny, Damian, Watsonia North, Australia
Tang, Cho, Moraga, CA, United States
Holme, Kevin R., Alameda, CA, United States
Galardy, Richard E., Guilford, CT, United States
Schultz, Gregory S., Gainesville, FL, United States
Nematalia, Asaad, Alameda, CA, United States
Musser, John H., San Carlos, CA, United States
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)
The University of Florida, Gainesville, FL, United States (U.S. corporation)
PI US 5892112 19990406
AI US 1994-184727 19940121 (8)
RLI Continuation-in-part of Ser. No. US 1993-44324, filed on 7 Apr 1993 And a continuation of Ser. No. US 1992-881630, filed on 12 May 1992, now patented, Pat. No. US 5270326 which is a continuation of Ser. No. US 1990-616021, filed on 20 Nov 1990, now patented, Pat. No. US 5114953 , said Ser. No. US 44324 which is a continuation-in-part of Ser. No. US 1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5268384 which is a continuation of Ser. No. US 1991-747751, filed on 20 Aug 1991, now patented, Pat. No. US 5239078 And Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 which is a continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900 , said Ser. No. US 747751 which is a continuation-in-part of Ser. No. US 615798
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Oswecki, Jane C.
LREP Lyon & Lyon LLP
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 3113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic mammalian **matrix metalloprotease** inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian **matrix metalloprotease** activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.

L5 ANSWER 20 OF 29 USPATFULL
AN 1998:135148 USPATFULL
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
IN Campbell, David A., San Mateo, CA, United States
Patel, Dinesh V., Fremont, CA, United States
Xiao, Xiao-Yi, San Diego, CA, United States
PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)
PI US 5831004 19981103
AI US 1995-549345 19951027 (8)
RLI Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995,

now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Tsang, Cecilia J.; Assistant Examiner: Delacroix-Muirheid, C.
LREP Swiss, Gerald F., Stevens, Lauren L.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2313
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel inhibitors of **metalloproteases**, in particular **matrix metalloproteases**. The disclosed inhibitors are mercaptoketone and mercaptoalcohol compounds which are useful in pharmaceutical compositions and methods for treating or controlling disease states or conditions which involve tissue breakdown, for example, arthropathy, dermatological conditions, bone resorption, inflammatory diseases, and tumor invasion and in the promotion of wound healing.

L5 ANSWER 21 OF 29 USPATFULL
AN 1998:135060 USPATFULL
TI Phosphinic acid amides as **matrix metalloprotease** inhibitors
IN Pikul, Stanislaw, Mason, OH, United States
McDow-Dunham, Kelly Lynn, Loveland, OH, United States
De, Biswanath, Cincinnati, OH, United States
Taiwo, Yetunde Olabisi, West Chester, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5830915 19981103
AI US 1997-918950 19970826 (8)
PRAI US 1996-24765P 19960828 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: O'Sullivan, Peter
LREP Hake, Richard A., McMahon, Mary Pat, Suter, David L.
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds which are useful as inhibitors of **matrix metalloproteases**, and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula (I) ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are described in the claims, a stereoisomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, ester acyloxyamide, imide or derivative thereof.

Also disclosed are compounds, pharmaceutical compositions and methods of treating diseases characterized by **matrix metalloprotease** activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 22 OF 29 USPATFULL
AN 1998:75584 USPATFULL
TI Synthetic **matrix metalloprotease** inhibitors and use thereof

IN Levy, Daniel E., Alameda, CA, United States
Grobelny, Damian, Watsonia North, Australia
Tang, Cho, Moraga, CA, United States
Holme, Kevin R., Alameda, CA, United States
Galardy, Richard E., Guilford, CT, United States
Schultz, Gregory S., Gainesville, FL, United States
Nematalia, Asaad, Alameda, CA, United States
Musser, John H., San Carlos, CA, United States
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)
The University of Florida, Gainesville, FL, United States (U.S. corporation)
PI US 5773438 19980630
AI US 1994-464927 19940605 (8)
RLI Division of Ser. No. US 1994-184727, filed on 21 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-44324, filed on 7 Apr 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5268384, issued on 7 Dec 1993 which is a continuation-in-part of Ser. No. US 1990-477751, filed on 9 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 which is a continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900, issued on 2 Feb 1993 which is a continuation-in-part of Ser. No. US 1992-881630, filed on 12 May 1992, now patented, Pat. No. US 5270326, issued on 14 Dec 1993 which is a continuation of Ser. No. US 1990-616021, filed on 21 Nov 1990, now patented, Pat. No. US 5114953, issued on 19 May 1992
DT Utility
FS Granted
EXNAM Primary Examiner: McKane, Joseph
LREP Lyon & Lyon LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic mammalian **matrix metalloprotease** inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian **matrix metalloprotease** activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.

L5 ANSWER 23 OF 29 USPATFULL
AN 97:115305 USPATFULL
TI Inhibition of angiogenesis by synthetic **matrix metalloprotease** inhibitors
IN Galardy, Richard E., Suilford, CT, United States
PA Glycomed, Inc., Alameda, CA, United States (U.S. corporation)
PI US 5696147 19971209
AI US 1993-161786 19931203 (8)
RLI Continuation of Ser. No. US 1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5268384 which is a continuation-in-part of Ser. No. US 1991-747751, filed on 20 Aug 1991, now patented, Pat. No. US 5239078 Ser. No. Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 And Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900
DT Utility
FS Granted
EXNAM Primary Examiner: McKane, Joseph
LREP Lyon & Lyon LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 1461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic mammalian **matrix metalloprotease** inhibitors are useful in controlling angiogenesis. These compounds are thus useful in controlling the growth of tumors and in controlling neovascular glaucomas.

L5 ANSWER 24 OF 29 USPATFULL
AN 97:88979 USPATFULL
TI Lactam-containing hydroxamic acids
IN De, Biswanath, Cincinnati, OH, United States
Wahl, Christopher Thomas, Hamilton, OH, United States
Natchus, Michael George, Cincinnati, OH, United States
Cheng, Menyan, West Chester, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5672598 19970930
AI US 1995-407839 19950321 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Bond, Robert T.
LREP Suter, David L., Hake, Richard A., Roof, Carl J.
CLMN Number of Claims: 2
ECL Exemplary Claim: 1,2
DRWN No Drawings
LN.CNT 1837
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds that exhibit inhibitory activity against **matrix metalloproteases** ("MMPs"). Because MMPs are known to play a role in tissue degradation, the compounds of the present invention may be useful in preventing or treating diseases associated with excess MMP activity. In particular, the compounds have a structure according to Formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are various substituents as described in the specification; and Q is an alkyl chain, an alkenyl chain, a heteroalkyl chain, or a heteroalkenyl chain, wherein said chain has 2, 3, or 4 chain atoms and is unsubstituted or substituted with one or more alkyl moieties; or a pharmaceutically-acceptable salt, or biohydrolyzable alkoxyamide, acyloxyamide, or imide thereof. Preferred are those compounds where Q is an alkyl chain having 2, 3 or 4 chain atoms.

The invention also relates to pharmaceutical compositions comprising these compounds, and methods for preventing or treating diseases associated with unwanted MMP activity using the compounds and compositions.

L5 ANSWER 25 OF 29 USPATFULL
AN 97:51993 USPATFULL
TI Hydroxamic acid-containing inhibitors of **matrix metalloproteases**
IN Yelm, Kenneth Edward, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5639746 19970617
AI US 1994-366062 19941229 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Conrad, Joseph
LREP Roof, Carl J., Hake, Richard A., Clark, Karen F.
CLMN Number of Claims: 16

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1062
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides hydroxamic acid-containing compounds which are useful as inhibitors of **matrix metalloproteases** and which are effective in treating conditions associated with excess activity of these enzymes. In particular, the present invention relates to a compound having a structure according to Formula I ##STR1## wherein (A)R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are independently selected from various substituents; and

(B) where R.sup.3 and R.sup.4 or R.sup.4 and R.sup.5 may together comprise a cyclic moiety; or a pharmaceutically-acceptable salt, biohydrolyzable amide or biohydrolyzable ester thereof.

In other aspects, the invention is directed to pharmaceutical compositions containing the compounds of Formula (I), and to methods of treating diseases characterized by **matrix metalloprotease** activity using these compounds or the pharmaceutical compositions containing them.

L5 ANSWER 26 OF 29 USPATFULL
AN 93:102796 USPATFULL
TI Inhibition of angiogenesis by synthetic **matrix metalloprotease** inhibitors
IN Galardy, Richard E., 73 Faulkner Dr., Suilford, CT, United States 06437
PI US 5268384 19931207
AI US 1992-817039 19920107 (7)
RLI Continuation-in-part of Ser..No. US 1991-747751, filed on 20 Aug 1991, now patented, Pat. No. US 5239078 And a continuation-in-part of Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 And a continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900
DT Utility
FS Granted
EXNAM Primary Examiner: Springer, David B.
LREP Cagan, Felissa H., Giotta, Gregory J.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic mammalian **matrix metalloprotease** inhibitors are useful in controlling angiogenesis. These compounds are thus useful in controlling the growth of tumors and in controlling neovascular glaucomas.

L5 ANSWER 27 OF 29 USPATFULL
AN 93:70003 USPATFULL
TI **Matrix metalloprotease** inhibitors
IN Galardy, Richard E., Guilford, CT, United States
Grobelny, Damian, Macleod West, Australia
Musser, John H., Alameda, CA, United States
PA Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)
PI US 5239078 19930824
AI US 1991-747751 19910820 (7)
RLI Continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990
DT Utility
FS Granted
EXNAM Primary Examiner: Springer, David B.
LREP Murashige, Kate H., Giotta, Gregory J.

CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1125
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;

R.sup.3 is H or alkyl (1-4C);

R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;

n is 0, 1 or 2;

m is 0 or 1; and

x is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); or

X is an amino acid residue or amide thereof; or

X is the residue of a cyclic amine or heterocyclic amine;

Y is selected from the group consisting of R.sup.7 ONR.sup.6 CONR.sup.6 -, R.sup.6.sub.2 NCONOR.sup.7 -, and R.sup.6 CONOR.sup.7 -, wherein each R.sup.6 is independently H or lower alkyl (1-4C); R.sup.7 is lower alkyl (1-4C) or an acyl group; and

wherein --CONR.sup.3 -- is optionally in modified isoteric form are inhibitors of **matrix metalloproteases**.

L5 ANSWER 28 OF 29 USPATFULL
AN 93:14707 USPATFULL
TI **Matrix metalloprotease** inhibitors
IN Galardy, Richard E., 73 Faulkner Dr., Guilford, CT, United States 06437
Grobelny, Damian, 10 Victoria Ave., Macleod West, 3085, Australia
PI US 5189178 19930223
AI US 1991-747752 19910820 (7)
RLI Continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990
DT Utility
FS Granted
EXNAM Primary Examiner: Springer, David B.
LREP Murashige, Kate H., Giotta, Gregory J., Cagan, Felissa H.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;

R.sup.3 is H or alkyl (1-4C);

R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;

n is 0, 1 or 2;

m is 0 or 1; and

X is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); or

X is an amino acid residue or amide thereof; or

X is the residue of a cyclic amine or heterocyclic amine;

wherein R.sup.6 is H or lower alkyl (1-4C) and R.sup.7 is H, lower alkyl (1-4C) or an acyl group, and wherein --CONR.sup.3 -- is optionally in modified isosteric form

are useful for treating conditions which are characterized by unwanted **matrix metalloprotease** activities.

L5 ANSWER 29 OF 29 DGENE (C) 2002 THOMSON DERWENT
AN ABB77184 Peptide DGENE
TI New **human matrix metalloprotease** gene and protein, useful for diagnosing, staging, preventing or treating cancer or inflammatory diseases (e.g. arthritis), as well as in screening drugs for treating these diseases -
IN Falduto M T; Magnuson S R; Morgan D W
PA (FALD-I) FALDUTO M T.
(MAGN-I) MAGNUSON S R.
(MORG-I) MORGAN D W.
PI US 2002031817 A1 20020314 44p
AI US 1999-391104 19990907
PRAI US 1997-814394 19970311
DT Patent
LA English
OS 2002-361182 [39]
AB The sequence represents the **matrix metalloprotease** protein **zinc** binding consensus sequence, presents in the putative catalytic domain. The invention relates to a novel polynucleotide, which comprises a nucleotide sequence encoding a **human matrix metalloprotease** protein (designated MMP-ABT). The protein of the invention has cytostatic, anti-inflammatory, and anti-arthritic activity. The polynucleotide may have a use in gene therapy. The MMP-ABT polynucleotides and proteins are useful for detecting, diagnosing, staging, monitoring, prognosing, preventing or treating cancer or inflammatory diseases (e.g. arthritis). The MMP-ABT proteins and polynucleotides are also useful developing therapeutic agents that affect MMP function.

=>
<------User Break------>